Ivermectol represents a significant advancement in antiparasitic therapy, offering healthcare professionals a potent and selective treatment option for a range of parasitic infestations. As a semi-synthetic derivative of avermectin B1, it exhibits high affinity for glutamate-gated chloride channels found in nerve and muscle cells of invertebrates, leading to increased cell permeability and paralysis of target parasites. Its broad-spectrum activity, combined with a well-documented safety profile when used appropriately, makes it a cornerstone in both human and veterinary parasitology. This product card provides a comprehensive overview of Ivermectol’s pharmacological characteristics, clinical applications, and essential prescribing information for medical practitioners.

Features

• Contains ivermectin as the active pharmaceutical ingredient
• Available in 3 mg and 6 mg scored tablets for precise dosing
• High bioavailability with peak plasma concentrations within 4 hours post-administration
• Extensive tissue distribution with particularly high concentrations in liver and adipose tissue
• Plasma half-life of approximately 18 hours, allowing for once-daily dosing
• Primarily metabolized by liver CYP450 enzymes with fecal excretion
• Manufactured under cGMP standards with consistent batch-to-batch quality
• Blister-packed tablets with desiccant to maintain stability

Benefits

• Effectively eliminates a broad spectrum of nematode parasites through selective binding
• Provides rapid symptomatic relief by paralyzing and killing parasitic organisms
• Single-dose regimen for many indications improves patient compliance
• Minimal absorption in humans reduces systemic exposure and adverse effects
• Well-tolerated profile with majority of patients experiencing no significant side effects
• Cost-effective treatment option for mass drug administration programs

Common use

Ivermectol is primarily indicated for the treatment of various parasitic infections including strongyloidiasis caused by Strongyloides stercoralis, onchocerciasis (river blindness) caused by Onchocerca volvulus, and lymphatic filariasis when used in combination with other antiparasitic agents. It demonstrates efficacy against cutaneous larva migrans, scabies caused by Sarcoptes scabiei, and head lice infestations. Off-label uses include treatment of certain ectoparasitic infections and as part of combination therapy for resistant cases of parasitic diseases. The medication is particularly valuable in endemic regions where parasitic infections represent significant public health challenges.

Dosage and direction

Dosing is weight-based and indication-specific. For strongyloidiasis: 200 mcg/kg orally as a single dose. For onchocerciasis: 150 mcg/kg orally as a single dose, repeated every 6-12 months as needed. Tablets should be taken with water on an empty stomach at least 1 hour before food to maximize absorption. For patients with difficulty swallowing, tablets may be crushed and mixed with a small amount of water. Dosage adjustments are required for pediatric patients and those with hepatic impairment. Treatment may need to be repeated based on follow-up stool examinations or clinical assessment.

Precautions

Exercise caution in elderly patients due to potential age-related decreases in hepatic function. Monitor patients with hepatic impairment closely as metabolism may be reduced. Use during pregnancy only if potential benefits justify potential risks to the fetus. Breastfeeding should be interrupted during treatment and for 72 hours post-dose. Patients should be advised that temporary worsening of pruritus may occur due to parasite death. Those with high microfilarial loads may experience Mazzotti-like reactions requiring symptomatic treatment. Driving and operating machinery should be avoided if dizziness or vertigo occurs.

Contraindications

Hypersensitivity to ivermectin or any component of the formulation. Concomitant use with other medications that increase blood-brain barrier permeability. Patients with conditions that compromise the blood-brain barrier, including meningitis and African trypanosomiasis. History of severe allergic reactions to similar macrocyclic lactone compounds. Not recommended for children weighing less than 15 kg unless specifically indicated and carefully monitored.

Possible side effect

Common reactions (≥1% incidence) include pruritus, rash, fever, headache, dizziness, and musculoskeletal pain. Gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort may occur. Less frequently reported effects (0.1-1% incidence) include orthostatic hypotension, tachycardia, and transient eosinophilia. Rare adverse events (<0.1% incidence) include elevated liver enzymes, visual disturbances, and exacerbation of asthma. Severe reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis have been reported exceptionally rarely.

Drug interaction

Ivermectol may interact with warfarin, potentially increasing anticoagulant effect through protein binding displacement. Concurrent use with CYP3A4 inhibitors (ketoconazole, ritonavir) may increase ivermectin concentrations. Inducers of CYP3A4 (rifampin, carbamazepine) may decrease efficacy. Enhanced CNS effects possible when used with benzodiazepines or other sedative agents. Caution advised with concomitant use of other QTc-prolonging medications. Monitor patients closely when administered with drugs that affect P-glycoprotein transport.

Missed dose

If a dose is missed, it should be taken as soon as remembered unless it is nearly time for the next scheduled dose. Do not double the dose to make up for a missed administration. For monthly prophylactic regimens, take the missed dose and resume the regular schedule. Contact healthcare provider if multiple doses are missed or if uncertainty exists about dosing schedule.

Overdose

Symptoms of overdose may include exaggerated pharmacological effects including nausea, vomiting, diarrhea, dizziness, urticaria, and hypotension. In severe cases, CNS depression including ataxia, respiratory depression, and coma may occur. There is no specific antidote. Treatment is supportive and symptomatic. Gastric lavage may be considered if administered within 1 hour of ingestion. Activated charcoal may help reduce absorption. Hemodialysis is not effective due to high protein binding. Monitor vital signs and provide symptomatic care as needed.

Storage

Store at controlled room temperature between 15-30°C (59-86°F). Protect from light and moisture. Keep in original blister packaging until time of use. Do not freeze. Keep out of reach of children and pets. Discard any tablets that show signs of physical deterioration or are beyond the expiration date printed on packaging. Do not transfer to alternative containers as this may compromise stability.

Disclaimer

This information is intended for healthcare professionals and should not replace clinical judgment. Prescribers should consult full prescribing information before administration. Dosage must be individualized based on patient characteristics and specific parasitic infection. Efficacy and safety in specific patient populations may vary. Report adverse events to appropriate regulatory authorities. The prescriber should verify the diagnosis before initiating treatment.

Reviews

Clinical studies demonstrate Ivermectol achieves parasitological cure rates of 85-95% for strongyloidiasis with single-dose administration. In onchocerciasis treatment, studies show 90% reduction in microfilarial load sustained for 6-12 months post-treatment. Dermatological applications show complete resolution of scabies infestations in 70-80% of patients with single dose, increasing to 95% with second dose. Patient satisfaction surveys indicate high tolerability with 92% reporting minimal side effects. Long-term follow-up studies in endemic areas demonstrate significant reduction in disease transmission rates with community-wide administration programs.